Overall, these data suggest that treatment of SLE B cells with iberdomide significantly affects gene expression downstream of Ikaros and Aiolos, thus modulating a number of critical cellular survival pathways in differentiating B cells. This evidence concerns the gene IKZF3 and systemic lupus erythematosus.